Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CellPoint
Oegstgeest, Netherlands
- Ownership
- Private
- Development stage
- Other
01
Overview
CellPoint developed a decentralized CAR-T manufacturing platform that allows for a 7-day vein-to-vein time (from T-cell collection to CAR-T infusion) compared to the industry standard of over a month. Their first proprietary CD19 CAR-T investigational therapy was in Phase 1/2a trials as of 2022.
- Therapeutic areas
- Oncology
- Modalities
- CAR-T cell therapies
- Industry
- Biotech
02
Partnerships
Strategic collaboration with Lonza (for the Cocoon® system)
Beyond the preview
Go deeper on CellPoint.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CellPoint.